Home・Akciju saraksts・Vir Biotechnology Inc

Vir Biotechnology Inc

Slēgts

SektorsVeselības aprūpe

9.19 2.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.92

Max

9.19

Galvenie mērījumi
By Trading Economics
Ienākumi	80M -46M
Pārdošana	239M 239M
EPS	0.47
Peļņas marža	-19.09
Darbinieki	367
EBITDA	201M 78M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+136.56% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 4. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	3.3M 1.5B
Iepriekšējā atvēršanas cena	6.97
Iepriekšējā slēgšanas cena	9.19

Ziņu noskaņojums

By Acuity

20%

80%

46 / 340 Rangs Healthcare

Vir Biotechnology Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. aug. 19:36 UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

2026. g. 10. aug. 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

2026. g. 7. aug. 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

2026. g. 6. aug. 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

2026. g. 5. aug. 23:41 UTC

News

Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

2026. g. 3. aug. 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

2026. g. 29. jūl. 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

2026. g. 28. jūl. 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

2026. g. 27. jūl. 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

2026. g. 25. jūl. 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

2026. g. 24. jūl. 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

2026. g. 21. jūl. 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

2026. g. 20. jūl. 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Salīdzinājums

Cenas izmaiņa

Vir Biotechnology Inc Prognoze

Cenas mērķis

By TipRanks

136.56% augšup

Prognoze 12 mēnešiem

Vidējais 21.29 USD 136.56%

Augstākais 30 USD

Zemākais 15 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Vir Biotechnology Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Vir Biotechnology Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

46 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.